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Abstract
Background: “Vulnerable Elders Survey” (VES-13) is a questionnaire accurate in predicting functional decline and
highly correlated with comprehensive geriatric assessment in identifying vulnerable elderly. The purpose of this
study was to translate, cultural adapt and validate the first Portuguese cross-cultural version of VES-13 and to
estimate the prevalence of vulnerability in Portuguese elderly gastrointestinal (GI) cancer patients.
Methods: VES-13 European Portuguese translation and cultural adaptation was developed according to
internationally accepted guidelines. Test-retest reliability and internal consistency were assessed by calculating the
Kappa statistic and by analyzing the inter-item and item-total correlation matrices and calculation of Cronbach’s
alpha coefficients, respectively. Construct and criterion validity was assessed by Spearman’s correlation coefficient
between VES-13 and each EQ-5D-5 L dimension, clinical judgment and performance status.
Results: The translated and culturally adapted version of VES-13 revealed high test-retest reliability (test-retest
Kappa ≥ 0.612; p < 0.001) in the pilot study (n = 22). For the validation phase 206 patients with GI cancer were
recruited (median age: 73 years; colo-rectal cancer: 63 %). Criterion validity was confirmed by adequate correlations
between VES-13 and clinical judgment of vulnerability, ECOG and KPS scores. Construct validity was confirmed by
moderate correlations with most of EQ-5D-5 L dimensions. Cronbach’s alpha of the questionnaire was 0.848.
The estimated prevalence of vulnerability is 50 % (CI95% 0.43-0.56).
Conclusions: The European Portuguese version of VES-13 is a valid and reliable approach to screening elderly
cancer patients for geriatric needs. In our setting, one in two elderly patients was likely to be vulnerable or frail
which stresses the importance of their correct identification to better inform cancer management.
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Background
As the western population ages overall cancer burden
will increase [1]. Cancer of the digestive tract accounts
for 30 % of new cancer cases per year and 60 % of these
are diagnosed in patients older than 65 years [1]. In
Portugal, gastro-intestinal (GI) cancer is the most inci-
dent cancer and approximately 10,000 new cases per
year are diagnosed in patients ≥ 65 years old [2].
Elderly cancer patients are a heterogeneous popula-
tion. They are more likely to present multiple co-morbid
conditions and are more frequently affected by polyphar-
macy, depression and cognitive impairment than youn-
ger individuals [3–8]. Moreover, because this population
is frequently under-represented in clinical trials the ef-
fectiveness and toxicity profile of standard treatment
protocols are less well established for the elderly [4].
Both issues increase uncertainty when therapeutic deci-
sions have to be made [4].
The higher inter-individual variability of the elderly led
geriatric medicine to establish the concept of vulnerability
which attempts to describe patients with increased sus-
ceptibility to adverse outcomes [7]. In geriatric oncology,
vulnerability is also associated with prognosis [9-11].
The best way to identify vulnerability is through a biop-
sychosocial evaluation commonly known as comprehen-
sive geriatric assessment (CGA) [6, 12].But a full CGA is
time and human resource consuming, making its incorp-
oration into current clinical practice less feasible [6]. The
“Vulnerable Elders Survey” (VES-13), a 13-item self-
report questionnaire, distinguishes fit elders from the frail
or vulnerable ones. This tool has been shown to identify
elderly patients who would require a comprehensive geri-
atric evaluation [13–17]. However, no validated translation
to European Portuguese was available.
Our primary goal was to translate, culturally adapt and
validate the VES-13 questionnaire for the Portuguese
population. The secondary research objective was to es-
timate the prevalence of vulnerability in elderly patients
with GI neoplasms in Portugal.
Methods
Translation and face validity
The authors followed the European Organization for
Research and Treatment of Cancer (EORTC) guide-
lines - Quality of Life Group Translation Procedure;
and Guillermin et al. recommendations [18, 19]. Briefly,
the original questionnaire was translated into European
Portuguese and culturally adapted by two healthcare pro-
fessionals with English fluency, knowledgeable of the
translation purpose. This draft version was translated back
into English, by two English translators, and compared to
the original questionnaire by the investigators and the ori-
ginal VES-13 authors, to assess comprehension of the
applied concepts and wording. No problems were identi-
fied at this stage.
Face validity of the translated questionnaire was assessed
by six medical oncologists at our GI Cancer Clinic. They
were asked to review the original and translated ques-
tionnaires and classify each question, according to com-
prehension and accuracy of the translation, using a
numerical rating scale of 10 points (1 - poorly clear, to
10 - completely clear).
Patient recruitment
Cancer patients admitted at our Comprehensive Cancer
Centre age ≥65 years with histologically confirmed GI
Cancer, Portuguese fluency, and no history of previous
systemic therapy for cancer were eligible for both the
pilot and prospective validation cohort. Patients present-
ing cognitive impairment, confusional syndrome or who
were illiterate or foreign individuals were excluded from
the pilot study. The pilot study also excluded patients
unable to read.
This work has been approved by the ethical committee
of the “Instituto Português de Oncologia do Porto” in
Portugal, institution where it was developed and all the
subjects gave their informed consent.
Pilot study: cultural adaptation and test-retest reliability
The questionnaire was applied by one of the investiga-
tors to included consecutive patients (first pilot n = 20,
second pilot n = 22) who were asked to rate each ques-
tion for comprehension using the previously described
numerical rating scale of 10 points. Each patient com-
pleted the VES-13 questionnaire twice within 1 to
30 days. At this point, a question was to be reviewed if it
had a single rating ≤5 (corresponding to reasonably
clear), or if any comprehension problem was noted by
the interviewer. Concerns regarding question 3f made
necessary a second pilot, after questionnaire adaptation.
Prospective cohort study: construct and criterion validity
After completion of the pilot study, the European
Portuguese version of VES-13 was prospectively ap-
plied to a cohort of 200 patients to assess internal
consistency and construct and criterion validity [20–22].
To assess construct validity we selected EQ-5D-5L as
comparator [23]. EQ-5D-5L is a generic health related
quality of life questionnaire which includes five dimen-
sions and a visual analogue scale (VAS) assessing general
health. Each dimension is recorded in five severity levels
(no problems, slight, moderate, severe and extreme prob-
lems, graded from 1 to 5, respectively). The VAS records
an individual’s rating for their current health-related qual-
ity of life (ranging from 0 - worst imaginable health, to
100 – best imaginable health). Predefined hypothesis
about relationships among dimensions of EQ-5D-5L and
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VES-13 were tested to assess construct validity. To assess
criterion validity we used the clinical impression of a
trained medical oncologist, blinded to the responses on
VES-13, regarding patient’s vulnerability and performance
status (PS). Each medical oncologist was instructed to
consider the Eastern Cooperative Oncology Group classi-
fication – ECOG [24] and Karnofsky scale – KPS [25],
and to categorize each patient into the following groups:
fit, vulnerable or frail. Performance status was estimated
according to exact ECOG PS and KPS scales definition
(ECOG PS ranging from 0 –able to carry on all pre-
disease performance without restriction, to 5 – dead; KPS
ranging from 100 – normal, no complaints, to 0 – dead).
Correlations among these criteria and VES-13 were evalu-
ated to assess criterion validity.
Statistical analysis
Patient’s demographics and clinical characteristics were
studied using descriptive statistics as appropriate.
Numerical variables were described with means and
standard deviation or with medians and interquartile
ranges, depending on the asymmetry of their distribu-
tions. Categorical variables were described as absolute
and relative (percentages) frequencies. Performance sta-
tus was categorized as follows: ECOG ≤1 and ≥2 and
KPS 100–80 and ≤70. Charlson comorbidity index (CCI)
was used to estimate the burden of co-morbid condi-
tions. When testing hypothesis about continuous vari-
ables, Student’s t-tests were used to compare two groups
when normality assumptions were confirmed and
Mann–Whitney U tests were used if normality could not
be assumed). When testing hypothesis about categorical
variables, Chi-square test and Fisher’s exact test were
used as appropriate.
The test-retest reliability of the Portuguese version of
VES-13 was assessed in the pilot study by calculating
the Kappa statistic for each item to assess agreement be-
tween test and retest scores [26]. This index takes values
Table 1 Intra-individual classification and reliability of each VES-13
VES-13 question VAS for comprehension Test-retest reliability
median [interquartile range] Reliability coefficients (p)
Item 1 8.0 [8–9] 1.000 (<0.001)
Item 2 8.0 [8–9] 0.736 (<0.001)
Item 3a 8.0 [8–9.25] 0.771 (<0.001)
Item 3b 8.0 [8–9.25] 0.612 (<0.001)
Item 3c 8.0 [8–9.25] 0.906 (<0.001)
Item 3d 8.0 [8–9.25] 0.792 (<0.001)
Item 3e 8.5 [8–9.25] 0.938 (<0.001)
Item 3f 8.5 [8–9.25] 0.823 (<0.001)
Item 4a 8.5 [8–9.25] 0.911 (<0.001)
Item 4b 8.5 [8–9.25] 1.000 (<0.001)
Item 4c 8.5 [8–9.25] 0.831 (<0.001)
Item 4d 8.5 [8–9.25] 1.000 (<0.001)
Item 4e 8.5 [8–9.25] 1.000 (<0.001)
VES-13 Total Score - 0.924 (<0.001)
VES-13 – Vulnerable Elders Survey; VAS – Visual Analogue Scale; p – significance level
Reliability coefficients – Kappa statistic measuring agreement between test and retest individual items and Pearson’s correlation coefficient measuring reliability
between test and retest VES-13 total scale scores
Fig. 1 Flowchart of validation study selection process
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between −1 and 1; values near 1 show high test-retest re-
liability. The categorization by Landis and Koch was
used for interpretation of κ values (<0.00 – no agree-
ment; 0.01-0.20 – slight; 0.21-0.40 – fair; 0.41-0.60 –
moderate; 0.61-0.80 – substantial and 0.81-1.00 – almost
perfect agreement) [27]. Additionally, we calculated the
test-retest reliability coefficient (correlation coefficient)
for VES-13 total scale score.
Internal consistency of translated VES-13 items was
explored by analyzing the inter-item and item-total cor-
relation matrices and calculation of Cronbach’s alpha co-
efficients. This coefficient ranges from 0 to 1, and larger
values indicate higher internal consistency. As recom-
mended by Nunnally and Bernstein, alphas ≥0.70 were
considered adequate [21]. An estimation of Cronbach’s
alpha if an item were to be deleted from the scale was
used to identify which items affected the questionnaire’s
internal consistency the most.
Construct and criterion validity was assessed by calcu-
lating Spearman’s correlation coefficient between VES-
13 and each EQ-5D-5L dimension, clinical judgment
and performance status. Interpretation of correlation co-
efficients was based on the quantitative criteria and
qualitative descriptors defined by Cohen [28] (low corre-
lations for coefficients with absolute value between 0.10
and 0.29; moderate correlations for coefficients between
0.30 and 0.49 and high correlations for coefficients be-
tween 0.50 and 1.00).
Exploratory factor analysis for VES 13 European
Portuguese version was performed using principal com-
ponents analysis for factor extraction. The hypothesis of
unidimensionality of VES-13 was assessed. Selection of
the number of factors to retain took into account Kai-
ser’s criterion (eigenvalues larger than one); graphical
analysis of the Scree-plot; and the total variance ex-
plained. If adequate, to improve interpretation of factors,
orthogonal varimax rotations were to be applied. The
Kaiser-Meyer-Olkin (KMO) measure and the Bartlett’s
test of sphericity were assessed.
Finally, we performed a ROC curve analysis, to assess
the best cutoff point for VES-13 total score for discrim-
ination of Frail/Vulnerable elders, assuming the attend-
ing physician’s clinical judgment as the gold standard.
Best cutoff selection criterion was based on the method
of minimization of the distance to the left upper corner
of the ROC plot, calculated as √(1-Sn)2 + (1-Sp)2.
A prospective cohort of 200 consecutively enrolled se-
nior GI cancer patients (≥65 years), would allow an esti-
mation of the prevalence of vulnerability/frailty with a
95 % confidence level margin of error of 0.07. This sam-
ple size would also allow an estimation of validity coeffi-
cients (correlation coefficients) larger than 0.20, with
95 % confidence level and 90 % power.
Statistical analysis was performed using the Statistical
Package for the Social Sciences Version 20.0 for Win-
dows (SPSS®). Whenever statistical hypothesis testing
was used, a significance level of α = 5 % was considered.
Results
Translation and cultural adaptation
After translation and cultural adaptation, all ques-
tions scored 6 or higher, corresponding to reasonable
Table 2 Clinical and demographic characteristics
VES-13 < 3 VES-13≥ 3 Total
n = 104 (%) n = 102 (%) n = 206 (%)
Male 77 (74) 56 (55) 133 (65)
Age - years, median [range] 72 [65–84] 77 [65–89] 73 [65–89]
Charlson comorbidity index, median [range] 6 [5–15] 8 [5–15] 7 [5–15]
Diabetes mellitus 29 (28) 33 (32) 62 (30)
Cardiovascular disease 12 (12) 24 (24) 36 (17)
No. concomitant drugs, median [range] 3 [1–9] 4 [1–8] 3 [1–9]
Primary cancer topography
Colorectal 66 (64) 64 (63) 130 (63)
Gastro-esophageal 29 (28) 24 (24) 53 (26)
Pancreas 3 (3) 10 (10) 13 (6)
Cancer stage (AJCC 7th edition)
I 9 (9) 8 (8) 17 (8)
II 23 (22) 20 (20) 43 (21)
III 43 (42) 34 (33) 77 (37)
IV 22 (21) 34 (33) 56 (27)
VES-13 – Vulnerable Elders Survey: < 3→ fit; ≥ 3→ vulnerable/fragile; AJCC – American Joint Committee of Cancer
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comprehension during face validation and no changes
were deemed necessary.
The pilot study included 20 patients and comprehen-
sion difficulties were apparent to the interviewer for
male patients answering two questions that included ex-
amples of household tasks. These problems were dis-
cussed with the original VES-13 authors, and the
Portuguese questionnaire was adapted with the inclusion
of different domestic tasks examples. A second pilot test
was implemented with 22 patients and no difficulties
were noted. All questions scored 6 or higher in VAS and
test-retest reliability revealed substantial to perfect
agreement between test and retest for individual items
(test-retest Kappa ranging from 0.612 to 1.000, p <
0.001) and very high correlation between test and retest
VES-13 total scale scores, as shown in Table 1 [27].
Internal consistency and construct and criterion validity
The VES-13, EQ-5D-5L and medical oncologist’s clinical
assessment were applied during 6 months (June to No-
vember, 2012). During this period, 296 elderly patients
with GI Cancer were admitted to our GI Cancer Clinic
and a total of 206 patients were included (Fig. 1 de-
scribes the selection process and reasons for exclusion).
Demographic and clinical characteristics of the cohort
are described in Table 2. The 90 individuals not included
Table 3 Functional status and quality of life








No problems 72 (69) 16 (16)
Problems 32 (31) 86 (84)
Self-care <0.001
No problems 97 (93) 35 (34)
Problems 7 (7) 67 (66)
Usual activities <0.001
No Problems 84 (81) 20 (20)
Problems 20 (19) 82 (80)
Pain/discomfort 0.001
No problems 48 (46) 24 (24)
Problems 55 (54) 77 (76)
Anxiety/depression 0.193
No problems 34 (33) 25 (24)
Problems 69 (67) 76 (76)






Fit 85 (82) 33 (32)
Vulnerable/fragile 19 (8) 69 (68)
ECOG PERFORMANCE STATUS <0.001
0 58 (56) 13 (13)
1 46 (44) 38 (37)




100 28 (27) 6 (6)
90 48 (46) 17 (17)
80 26 (25) 29 (28)
≤70 2 (2) 50 (49)
VES-13 – Vulnerable Elders Survey: < 3→ fit; ≥ 3→ vulnerable/fragile;
VAS - Visual Analogue Scale; ECOG – Eastern Cooperative Oncology Group;* -
Chi-square test; p - significance level; **Mann–Whitney test
Table 4 VES-13 internal consistency
VES-13 question Classification
(points)
n (%) Cronbach’s alpha
if item deleted
Item 1 0 119 (58) 0.880
1 68 (33)
3 19 (9)
Item 2 0 61 (30) 0.849
1 145 (70)
Item 3a 0 155 (75) 0.829
1 51 (25)
Item 3b 0 162 (79) 0.829
1 44 (21)
Item 3c 0 184 (89) 0.835
1 22 (11)
Item 3d 0 194 (94) 0.847
1 12 (6)
Item 3e 0 164 (80) 0.829
1 42 (20)
Item 3f 0 118 (57) 0.826
1 88 (43)
Item 4a 0 156 (76) 0.827
4 50 (24)
Item 4b 0 178 (86) 0.835
4 28 (14)
Item 4c 0 189 (92) 0.836
4 17 (8)
Item 4d 0 165 (80) 0.833
4 41 (20)




- - - 0.848
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in the sample had epidemiological and clinical character-
istics similar to those included in the study.
The cohort’s median age was 73 years (29 % ≥80 years)
and 65 % of the subjects were male. Colorectal cancer
was the most frequent tumor location (63 %) and 3 % of
patients had a history of previous neoplasms. The most
prevalent co-morbidities were diabetes (n = 62, 30 %)
and cardiovascular disorders (n = 36, 17 %). The median
CCI was 7 (interquartile range: 6–11). Fifty-eight pa-
tients (28 %) were taking five or more daily drugs, and
the more frequent therapeutic groups, as defined by the
World Health Organization Anatomical Therapeutic
Chemical/Defined Daily Dose, were “cardiovascular sys-
tem” and “alimentary tract and metabolism” drugs.
Compliance with VES-13 and EQ-5D-5L question-
naires was 100 %, except for EQ-5D-5L questions “pain/
discomfort”, “anxiety/depression” and VAS scale, which
were above 98 %. Summary results for quality of life
assessed using EQ-5D-5L are presented in Table 3. A
proportion greater than 70 % of patients indicated that
they were facing no problems or slight problems in all
EQ-5D-5L dimensions; “self-care” presented the highest
result with over 80 % of patients experiencing no prob-
lems or slight problems. Overall quality of life assess-
ment for the cohort revealed a median EQ-VAS score of
60 percent (interquartile range: 50–75).
VES-13 European Portuguese version of the question-
naire showed high internal consistency, with Cronbach’s
alpha if item deleted ranging from 0.826 to 0.880, and a
Cronbach’s alpha for the scale score of 0.848, Table 4.
When assessing the correlation of VES-13 and EQ-5D-
5L dimensions we obtained, as expected, higher correl-
ation scores for “mobility”, “self-care” and “usual activ-
ities” (rs: 0.634, 0.625 and 0.652 respectively). Although
not so strong, statistically significant correlations with
“pain/discomfort” (rs: 0.329) and “anxiety/depression”
(rs: 0.178) domains and with VAS scale (rs: −0,527) were
also observed. There were moderate to strong correla-
tions between VES-13 and clinical judgment, ECOG and
KPS scales (rs: −0.499, 0.599, and −0.576, respectively).






Usual activities 0.732 (<0.001)
Pain/discomfort 0.405 (<0.001)
Anxiety/depression 0.237 (0.001)
VAS (mean) −0.592 (<0.001)
CLINICAL JUDGMENT −0.570 (<0.001)
ECOG PS 0.614 (<0.001)
KPS −0.622 (<0.001)
Fig. 2 Distribution of VES-13 global score for the Fit and Vulnerable/Fragile elders, as classified by the clinical judgment of the attending physician
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Table 5 presents the summary statistics for the correl-
ation coefficients between VES-13 and EQ-5D-5L, per-
formance status and clinical impression. In Fig. 2 we can
also see and contrast the distribution of VES-13 total
score for the fit and vulnerable/fragile elders, as classi-
fied by the clinical judgment of the attending physician.
In Fig. 3 we present a ROC curve analysis of the VES-13
total score, assuming the clinical judgment of the attend-
ing physician as the gold standard; and showing the cut-
off value of >3 as the most appropriate for maximizing
both sensitivity and specificity. For this cutoff value the
sensitivity was 71 % and the specificity was 84 %. The es-
timate of the area under the ROC curve was C = 0.818
(95 % CI [0.762 – 0.875]).
Exploratory factor analysis, with factor extraction
using principal components, was performed for VES-13.
The factor solution included a first component with
eigenvalue 6.41 and 49.3 % of the variance explained, a
second component with eigenvalue 1.08 and 8.3 % of the
variance explained, and all other components with ei-
genvalues lower than 1.00 and smaller percentages of
variance explained. Based on the analysis of the scree
plot, the eigenvalues of the components and the per-
centage of the variance explained, the one factor solu-
tion was clearly the more appropriate, supporting the
hypothesis of unidimensonality of VES-13. Although
the strict application of the Kaiser rule would imply the
selection of a two factor solution, the fact is that the
second component had an eigenvalue marginally above
1.00 and a low percentage of variance explained, thus a
one factor solution is clearly a more sensible solution
in this case.
Loadings found in the one factor solution and the
KMO and Bartlett’s test of sphericity are presented in
Tables 6 and 7. It is possible to assess the adequacy of
the one factor solution by observing that loadings of
most items are above 0.6, with only the first item (Age
category) having a loading of 0.375; and taking into
Fig. 3 ROC curve analysis for the VES-13 total score. Legend : ROC curve analysis for the VES-13 total score, assuming the clinical judgment of the
attending physician as the gold standard, showing the cutoff value of >3 as the most appropriate for maximizing both sensitivity (71 %) and
specificity (84 %). The area under the ROC curve was C = 0.818 (95 % CI [0.762 – 0.875])
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consideration the high value of the KMO statistic (KMO
= 0.905) and the result of the Bartlett’s test (p < 0.001).
Prevalence of vulnerability in elderly patients with GI
cancer
The proportion of vulnerable elderly GI cancer patients
was 0.50 (CI95%: 0.43-0.56). Vulnerable patients were
more likely to have higher EQ-5D-5L scores on every di-
mension, meaning higher prevalence and magnitude of
problems, and lower EQ-VAS values, meaning a percep-
tion of worse quality of life. These patients also had
worse performance status (higher mean ECOG-PS and
lower KPS). Vulnerable patients had higher CCI scores
(p < 0.001) and were also more likely to have higher
polypharmacy levels (32 % versus 19 % of patients were
receiving ≥5 daily drugs).
Discussion
Aging results in physiologic decline and there is consen-
sus that oncologic treatment decisions should be based
on a patient’s biologic age rather than his chronologic
age [29, 30]. Multiple tools have been developed to iden-
tify vulnerability and frailty, but there is no consensus
on a single optimal approach. The International Society
of Geriatric Oncology (SIOG) considers VES-13 a useful
screening tool to identify vulnerable elders [31]. This
survey questionnaire predicts impaired functional status
but was not available in European Portuguese.
The proposed European Portuguese version presented
in this paper was developed according to internationally
accepted guidelines [18, 19]. After the translation proce-
dures, pilot studies were performed to assess comprehen-
sion difficulties and questionnaire translation adequacy.
Test-retest reliability of the questionnaire’s total score and
individual items was generally very high, expressed by
the high reliability coefficient for the total score and
the near 1.0 Kappa values for each individual item. In-
ternal consistency, which ensures the questionnaire de-
livers consistent and reliable scores was, for each item
and globally, high (Cronbach’s alpha of 0.848).
To assess construct validity we used EQ-5D-5L as
comparator. This tool includes five different dimensions




















VES-13 – Vulnerable Elders Survey. Eigenvalue and percentage of variance
explained for the one factor solution were 6.405 and 49.27 %, respectively.
KMO statistic was 0.905 and Bartlett’s test of sphericity had p < 0.001
Table 7 Inter-item correlation matrix (b) for the Portuguese version of VES-13
VES-13 question Item 1 Item 2 Item 3a Item 3b Item 3c Item 3d Item 3e Item 3f Item 4a Item 4b Item 4c Item 4d Item 4e
(b) Inter-item correlation matrix
Item 1 1.000 0.058 0.293 0.241 0.196 0.173 0.309 0.279 0.239 0.312 0.192 0.233 0.271
Item 2 0.058 1.000 0.385 0.461 0.387 0.440 0.483 0.523 0.398 0.262 0.406 0.418 0.326
Item 3a 0.293 0.385 1.000 0.674 0.677 0.597 0.614 0.607 0.443 0.312 0.462 0.432 0.525
Item 3b 0.241 0.461 0.674 1.000 0.676 0.561 0.592 0.685 0.487 0.344 0.477 0.421 0.461
Item 3c 0.196 0.387 0.677 0.676 1.000 0.616 0.498 0.512 0.502 0.371 0.452 0.456 0.466
Item 3d 0.173 0.440 0.597 0.561 0.616 1.000 0.560 0.504 0.466 0.369 0.489 0.358 0.550
Item 3e 0.309 0.483 0.614 0.592 0.498 0.560 1.000 0.714 0.454 0.298 0.478 0.504 0.519
Item 3f 0.279 0.523 0.607 0.685 0.512 0.504 0.714 1.000 0.493 0.346 0.367 0.472 0.580
Item 4a 0.239 0.398 0.443 0.487 0.502 0.466 0.454 0.493 1.000 0.563 0.436 0.497 0.489
Item 4b 0.312 0.262 0.312 0.344 0.371 0.369 0.298 0.346 0.563 1.000 0.357 0.292 0.415
Item 4c 0.192 0.406 0.462 0.477 0.452 0.489 0.478 0.367 0.436 0.357 1.000 0.360 0.478
Item 4d 0.233 0.418 0.432 0.421 0.456 0.358 0.504 0.472 0.497 0.292 0.360 1.000 0.505
Item 4e 0.271 0.326 0.525 0.461 0.466 0.550 0.519 0.580 0.489 0.415 0.478 0.505 1.000
VES-13 – Vulnerable Elders Survey. Eigenvalue and percentage of variance explained for the one factor solution were 6.405 and 49.27 %, respectively. KMO
statistic was 0.905 and Bartlett’s test of sphericity had p < 0.001
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with predictable relationships with the concept assessed
by VES-13. In the present study, in accordance with our
a priori predictions, a strong correlation was observed
between the EQ-5D-5L dimensions of “mobility”, “self-
care” and “usual activities” and VES-13. “Pain/discom-
fort” and “anxiety/depression” dimensions are not dir-
ectly assessed with VES-13; nonetheless, we found a
weak but statistically significant correlation. The EQ-
VAS obtained a negative correlation with VES-13 scores
because, as opposed to other dimensions, higher VAS
values are associated with higher perceived quality of
life, thus with less vulnerability. To assess criterion valid-
ity we used three different criteria that were assumed to
indirectly measure the vulnerability construct - clinical
judgment, ECOG PS and KPS. We used ECOG and KPS
even though there is strong criticism in their use on
geriatric oncology but these scales, standard measures
used in clinical practice, allowed us to make the criterion
validity of our instrument.
All were highly correlated with VES-13. In summary,
assessment of construct and criterion validity as per-
formed demonstrates the adequate validity of the trans-
lated and culturally adapted VES-13 European Portuguese
version. However, despite a correct identification of most
vulnerable patients, clinical judgment of vulnerability by a
trained medical oncologist classified 16 % of patients as fit
while VES-13 scored them as vulnerable/frail patients.
These results point to utility of the VES-13 as an initial
screen to identify who should go on to receive additional
comprehensive geriatric assessment before determining
their clinical classification.
Construct validity of VES-13 was also explored with
exploratory factor analysis, with factor extraction using
principal components; and the model described for
VES-13 revealed the appropriateness of the one factor
solution and the unidimensionality hypothesis. It is in-
teresting to notice that the loadings in the one factor so-
lution for each VES-13 item were very high (generally
above 0.6), however for the first item, age category
(“below 75 years old”, “between 75–84 years” and
“85 years or above”, with higher scores as age increases),
we observed a relevantly lower loading of 0.375, indicat-
ing that this was the single item with the lowest associ-
ation and consistency with the VES-13 total score and
the vulnerability/frailty construct. This is a very interest-
ing result that underlines the need for careful evaluation
of elderly cancer patients; as age, by itself, should not be
viewed as the most important factor when assessing an
elder as vulnerable/frail.
Internal validity is critical in any research study and
this judgment requires awareness of possible biases lim-
iting the study conclusions [32]. Withdrawal bias al-
though moderately high, as evidenced by a loss of 10 %
of potentially eligible patients, probably does not
invalidate our conclusions. Patients who were lost were
as likely to be given anti-cancer treatment as those in-
cluded and clinical and demographic characteristics were
similar between patients lost and those included (data
not shown). The main reason for loss of eligible patients
was the high clinical pressure on recruiting clinicians at
our institution, which mandated an adjustment to pa-
tient recruitment half way into the study. The investiga-
tors tried to avoid selection bias by establishing precise
inclusion and exclusion criteria. Nevertheless 4 % of ex-
cluded patients were too sick to answer, and thus fragile,
and some of the patients who were not assessed for in-
clusion might also have contributed to selection bias.
Response bias may have interfered with our conclusions,
since those who agreed to participate in the study may
be in some way different from those who refused to par-
ticipate. Should all of these potential biases have been
avoided it is our conviction that the estimated preva-
lence of vulnerability would be higher, therefore we be-
lieve that despite these limitations this is a valid
translation and validation of VES-13.
In our sample, approximately 1 in every 2 elderly can-
cer patients was identified as vulnerable or frail, which is
similar to several published reports (range between 47
and 60 %) [14, 15, 33]. However, persons screened as
vulnerable must be carefully evaluated, since the brief
VES-13 questionnaire can differ from the longer CGA in
identifying some senior patients as vulnerable [34].
Conclusions
In conclusion, the authors achieved a valid and reliable
European Portuguese European version of VES-13, to be
used as a first assessment of elderly cancer patients.
(Additional file 1). In our clinic, one in two elderly pa-
tients was likely to be vulnerable or frail. Therefore a
routine clinical practice assessment of the risk of vulner-
ability, with the use of tools like VES-13, and the develop-
ment of specialized multidisciplinary teams to perform a
comprehensive geriatric assessment, when needed, is para-
mount if we are to deliver high quality cancer care in an
aging population.
Additional file
Additional file 1: European Portuguese version of the Vulnerable
Elders Survey (VES-13). (PDF 207 kb)
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